I think shorts thought they'd capitalize on the offering, but many are staring at it now like deer in the headlights!
Let's do a little more consolidating, shall we? Here's to "Harry" ... I like his predictions!
Don't discount MDXG ... same space as OSIR and direct competition. Hedging with both ... new offering on MDXG at $6.80. Strength today, but we know now that works out, don't we?
UNIS strong yesterday in weak market on good volume ... little churn today, but moving towards $5 soon, imo.
A lot depends on where the offering is priced and market perception. However, I've experienced that sometimes the entity buying the shares does not always defend the share price. For instance, in ACRX, we had a large placement at $11.60ish and look where we stand now even after a successful NDA? I think sometimes they short it and make money both ways, but that's the cynic in me.
Disclaimer: own both MDXG and OSIR (doesn't hurt to hedge).
Yes, but market cap of OSIR is roughly 25% less than MDXG's. Better to concentrate on that. Very impressed with fairly strong volume ahead of the pricing!
people here told me it was a great buy
First of all bb ... it was a good buy ... today might be a better buy ... any lower it is a GREAT buy! A little air is being let out of a LOT of biotechs that have run hard this year. Question is, you KNOW it will bounce on Calcitriol news, so hang in there. Longer term story is intact here!
Well, people ... never CHASE a hot biotech. Patience is always borne out!! Buy the dips!
Would be nice on a weak market day to clear out this little resistance area that we hit the other day up near $4.50. If not, a little more consolidation and we will. "Looks weak"? I think not!
Oil analysts just explained that it has something to do with "moving oil around" for tax purposes end of year. Not as transparent as it might seem, nor as indicative of real demand or not.
Don't forget UNIS?
Look at NKTR ... same price action that we are experiencing.
Biotech profit taking? Sector up over 50% for the year?
Was just going to post that their price action looks a lot like ACRX ... profit taking in biotechs. The sector is up 59% for the year.
So what, if they tap the ATM. It really wouldn't shock anyone, would it? Gee, a biotech that needs cash! Alert the media!
From Wikipedia ...
In the United States, the Financial Industry Regulatory Authority, Inc. (FINRA) is a private corporation that acts as a self-regulatory organization (SRO). FINRA is the successor to the National Association of Securities Dealers, Inc. (NASD) and the member regulation, enforcement and arbitration operations of the New York Stock Exchange. It is a self-regulatory organization, a non-governmental organization that performs financial regulation of member brokerage firms and exchange markets. The independent government agency which acts as the ultimate regulator of the securities industry, including FINRA, is the Securities and Exchange Commission.
Buying dips has ALWAYS been the right strategy here ... those that have been here KNOW that. Buy the dips and sell them into the rips ... or, buy/accumulate and hold for the long term. Either way, ACRX will be just fine!!